8-K: Assertio Holdings Agrees to $21.80/Share All-Cash Acquisition by Garda

Assertio Holdings, Inc. has entered into an Amended and Restated Agreement and Plan of Merger with Garda Therapeutics, Inc., increasing the all-cash tender offer price to $21.80 per share.

Summary

• Assertio Holdings, Inc. has amended its merger agreement with Garda Therapeutics, Inc., increasing the all-cash tender offer price to $21.80 per share.
• The new offer represents a 21.1% premium over Garda's original offer and a 63.1% premium to Assertio's unaffected stock price prior to March 20, 2026.
• The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including the tender of a majority of Assertio's outstanding shares.
• Following the tender offer, Garda will acquire any remaining shares through a second-step merger at the same cash price.
• Assertio's Board of Directors unanimously approved the amended agreement and recommended that stockholders accept the offer.
• The company has withdrawn its previously disclosed 2026 guidance due to the transaction.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with the increased offer price and unanimous board approval indicating a strong outcome for Assertio shareholders.

Positives

• Increased all-cash offer price of $21.80 per share, a 21.1% premium to the original offer.
• The offer represents a significant premium (63.1%) to Assertio's unaffected stock price prior to March 20, 2026.
• The amended agreement provides greater cash consideration to Assertio stockholders.
• Fully-committed equity and debt financing commitments are in place for the transaction.
• The Board of Directors unanimously approved the offer, indicating it's the most favorable outcome for stockholders.

Negatives

• Assertio's common stock will no longer be listed on Nasdaq upon completion of the transaction.
• Assertio has withdrawn its previously disclosed 2026 guidance.
• The transaction is subject to customary closing conditions, including the tender of a majority of shares, which introduces some uncertainty.

Risks

• Risks associated with the timing of the closing of the transactions, including the possibility that a condition to closing would not be satisfied.
• Uncertainties as to how many of Assertio's stockholders will tender their shares in the Offer.
• The possibility that competing offers will be made.
• The possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transactions.
• The occurrence of any event, change or other circumstance that could give rise to the termination of the transactions.
• The outcome of any legal proceedings that may be instituted against the parties and others related to the transactions.
• Unanticipated difficulties or expenditures relating to the transactions.
• The effect of the announcement or pendency of the transactions on Assertio's business and operating results, including potential difficulties in employee retention.

Future Outlook

The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions. Upon completion, Assertio's common stock will no longer be listed on Nasdaq.

Management Comments

• "We are pleased with this outcome, which reflects the Boards focus throughout this disciplined and comprehensive process on delivering the best possible result for Assertios stockholders."
• "Gardas decision to increase its offer underscores both the competitive dynamics of the process and the underlying value of Assertio."
• "We would like to thank everyone involved for their dedication and execution throughout this process."

Industry Context

StockSavvy.ai notes that the increased offer price reflects a competitive M&A environment, potentially driven by the perceived value of Assertio's assets or market position, especially in the oncology sector. The withdrawal of guidance is typical in such acquisition scenarios as future strategic decisions will be made by the acquirer.

Legal Proceedings

• The filing mentions that the outcome of any legal proceedings instituted against the parties related to the transactions could differ materially from forward-looking statements.

Related Party Transactions

• Joseph M. Limber and Brett K.E. Lund, identified as Equity Investors, committed to purchase equity of Parent for an aggregate investment of $22,200,000.

Stakeholder Impact

• Shareholders will receive $21.80 per share in cash, representing a significant premium.
• Employees may face uncertainty regarding future employment and benefits post-acquisition, although the agreement outlines provisions for continued compensation and benefits for a period.
• The delisting from Nasdaq may impact liquidity and accessibility for some investors.

Next Steps

• Purchaser (Audi Merger Sub, Inc.) is required to commence the Offer on or before May 4, 2026.
• Assertio will file a Schedule 14D-9 with the SEC in connection with the tender offer.
• The transaction is expected to close in the second quarter of 2026.

Key Dates

Recommendation

While the increased offer price is positive, the transaction is still subject to closing conditions and potential competing offers. Investors should hold their position to await the tender offer results and final closing, while considering the potential for a higher offer or the risk of the deal not closing.

Keywords

Assertio Holdings, Garda Therapeutics, Merger Agreement, Tender Offer, Acquisition, Pharmaceutical, SEC Filing, Form 8-K